β-烟酰胺单核苷酸补充剂对中老年失眠疗效的相关研究

目的：观察和对比服用β-烟酰胺单核苷酸类膳食补充剂（NMN）与安慰剂对中老年人失眠的疗效，以及两种方法对此类人群中不同性别与年龄段人群的改善情况与疗效差异，并简要分析引起中老年人失眠原因和治疗失眠的机理。

方法：将58例符合标准的志愿者随机分为两组。治疗组（n=29）服用NMN治疗，对照组（n=29）服用安慰剂治疗。十二周后，通过两组治疗前后匹兹堡睡眠量表（PSQI）评分、智能手环睡眠数据的变化对比判断其疗效。

结果：1.二组在治疗前后的PSQI总分和各项均有下降。PSQI总分、睡眠效率和入睡时间的组间差异显著（P<0.05）。以PSQI总分判定疗效，二组总有效率也具有显著性差异（P<0.01）,治疗组的总有效率为65.5%，对照组仅为31.0%。说明β-烟酰胺单核苷酸类膳食补充剂具有改善失眠的疗效。

2. 治疗前后两组由华为智能手环记录的睡眠数据具有显著性差异（P<0.05，除REM比率外），治疗组相对于对照组的睡眠结构发生改变。具体表现为：深睡比率增加，浅睡比例减少，快速眼动期比率轻微增加，每周平均清醒次数减少。
3. 口服NMN对不同性别、各年龄段人群有着不同的疗效，并且具有统计学差异（P<0.05）。女性略好于男性，56~65周岁人群好于45~55周岁和66~75周岁人群。

结论：通过服用NMN治疗中老年人失眠的疗法有效，此次试验为临床治疗中老年人群失眠症提供了新的思路和方法；智能手环对睡眠监测具有可靠性，在一定程度上可以反映用户真实的睡眠情况，为临床监测技术提供新的路径。

[1] HIRSHKOWITZ M, WHITON K, ALBERT S M, et al. National Sleep Foundation's sleep time duration recommendations: methodology and results summary [J]. Sleep health, 2015, 1(1): 40-3.

[2] BLAY S L, ANDREOLI S B, GASTAL F L. Prevalence of self-reported sleep disturbance among older adults and the association of disturbed sleep with service demand and medical conditions [J]. Int Psychogeriatr, 2008, 20(3): 582-95.

[3] LEBLANC M F, DESJARDINS S, DESGAGNE A. Sleep problems in anxious and depressive older adults [J]. Psychology Research and Behavior Management, 2015, 8: 161-9.

[4] 艾瑞咨询. 2020 年 NMN 成分补剂消费者调研报告 [R]: 艾瑞咨询, 2020.

[5] 抗衰老保健品 NMN，千亿市场未来可期 [R]: 中信证券, 2020.

[6] 许飞, 陈正远. 中医药治疗失眠症研究进展 [J]. 中国中医药图书情 报杂志, 2022, 46(01): 72-6.

[7] 陈锦惠, 刘雯静, 詹晓亭, et al. 从中医古籍理论探究不寐与体质的 关系 [J]. 中国民族民间医药, 2022, 31(02): 4-10.

[8] 仇亚茹, 刘志亮, 陈分乔, et al. 梅建强教授治疗失眠症的思路 [J]. 天津中医药大学学报, 2019, 38(05): 420-3.

[9] 宋媛媛, 虞鹤鸣. 虞鹤鸣教授辨治失眠症经验分析 [J]. 西部中医药, 2020, 33(03): 52-5.

[10] 韩薪燃, 于睿, 张欢, et al. 于睿从肝论治失眠合并焦虑经验掬萃 [J]. 实用中医内科杂志, 2021, 35(04): 68-70.

[11] 孙卓, 刘龙涛. 从少阳论治失眠症的临证体悟 [J]. 中国医药导报, 2019, 16(36): 132-5.

[12] 吕书奇, 何华. 何华教授运脾和胃治疗失眠症经验总结 [J]. 中国中 医药现代远程教育, 2019, 17(18): 45-7.

[13] 王梦光, 刘冰, 车志英. 王国斌治疗失眠症经验 [J]. 国医论坛, 2018, 33(06): 21-3.

[14] 卢金荣, 李元, 白妍. 针刺辨证取穴治疗失眠症的临床应用进展 [J]. 中国中医药科技, 2020, 27(06): 1011-3.

[15] 刘志东. 不同证型原发性失眠症患者针刺方案的选择及疗效分析 [J]. 中国处方药, 2020, 18(01): 113-4.

[16] 吴限, 王毓岩, 罗珊珊. 李延治疗失眠症经验总结 [J]. 山东中医杂 志, 2016, 35(08): 730-1.

[17] 陈英群, 陈忆, 李桃桃, et al. 国医大师颜德馨从气血论治失眠症学 术思想撷英 [J]. 上海中医药杂志, 2019, 53(03): 1-4.

[18] 张栋. 十味温胆汤治疗痰热扰心型失眠的临床效果 [J]. 临床医学研 究与实践, 2017, 2(35): 101-2.

[19] 盛晓明. 黄连温胆汤加减治疗痰热扰心型失眠症的临床疗效 [J]. 名 医, 2019, (08): 274+7.

[20] 刘瑞利, 丁世芹. 清心镇肝汤治疗肝郁化火型失眠临床研究 [J]. 河 南中医, 2022, 42(02): 293-6.

[21] 何强. 解郁泻火安神汤治疗肝郁化火型失眠的疗效观察 [J]. 当代医 药论丛, 2020, 18(07): 193-4.

[22] 樊娟, 钱兵. 定寐汤治疗心肾不交型老年不寐临床观察 [J]. 山西中 医, 2020, 36(12): 39-40.

[23] 黄陈敏, 周洪武, 钟志明. 天王补心丹合交泰丸加减治疗心肾不交 型失眠效果观察 [J]. 中国乡村医药, 2020, 27(14): 34-5.

[24] 海月尔江·吾吉, 莫拉地江·莫合塔. 探讨芪枣安神汤对心脾两虚 型失眠症患者睡眠质量的影响研究 [J]. 世界睡眠医学杂志, 2019, 6(02): 169-70.

[25] 林娜. 归脾汤治疗心脾两虚型不寐患者的疗效观察 [J]. 西藏医药, 2022, 43(01): 146-8.

[26] 赵伟呐. 血府逐瘀汤加减治疗瘀血内阻型失眠的临床观察 [D]; 河 南中医药大学, 2018.

[27] 王美莺. 宁神安眠汤对心胆气虚证不寐患者睡眠质量的影响 [J]. 世 界睡眠医学杂志, 2018, 5(11): 1283-6.

[28] 殷忠. 参芍片联合温胆汤治疗心胆气虚型失眠的临床效果 [J]. 内蒙 古中医药, 2021, 40(04): 14-5.

[29] LAUNOIS S H, PEPIN J L, LEVY P. Sleep apnea in the elderly: a specific entity? [J]. Sleep Med Rev, 2007, 11(2): 87-97.

[30] MATTIS J, SEHGAL A. Circadian Rhythms, Sleep, and Disorders of Aging [J]. Trends in Endocrinology & Metabolism, 2016, 27(4): 192- 203.

[31] 肖余粮. 睡眠脑电的特性分析和睡眠分期研究 [D]; 江苏大学, 2006.

[32] International Classification of Sleep Disorders. 3rd ed: [S]. American Academy of Sleep Medicine: 2014:

[33] VGONTZAS A N, FERNANDEZ-MENDOZA J. Insomnia with Short Sleep Duration: Nosological, Diagnostic, and Treatment Implications [J]. Sleep Med Clin, 2013, 8(3): 309-22.

[34] SPIELMAN A J, CARUSO L S, GLOVINSKY P B. A behavioral perspective on insomnia treatment [J]. Psychiatr Clin North Am, 1987, 10(4): 541-53.

[35] BREWSTER G S, RIEGEL B, GEHRMAN P R. Insomnia in the Older Adult [J]. Sleep Med Clin, 2018, 13(1): 13-+.

[36] PERLIS M, GEHRMAN P, ELLIS J. The Natural History of Insomnia: What We Know, Don’t Know, and Need to Know [J]. Sleep Med Res, 2011, 2(3): 79-88.

[37] LINEBERGER M D, CARNEY C E, PHD' J D E, et al. Defining insomnia: Quantitative criteria for insomnia severity and frequency [J]. Sleep, 2006, 29(4): 479-85.

[38] LI J X, VITIELLO M V, GOONERATNE N S. Sleep in Normal Aging [J]. Sleep Med Clin, 2018, 13(1): 1-+.

[39] LICHSTEIN K L, DURRENCE H H, TAYLOR D J, et al. Quantitative criteria for insomnia [J]. Behav Res Ther, 2003, 41(4): 427-45.

[40] DRAKE C L, PILLAI V, ROTH T. Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia [J]. Sleep, 2014, 37(8): 1295-304.

[41] LEVENSON J C, KAY D B, BUYSSE D J. The Pathophysiology of Insomnia [J]. Chest, 2015, 147(4): 1179-92.

[42] KORANYI N, MEINHARD M, BUBLAK P, et al. Automatic affective responses towards the bed in patients with primary insomnia: evidence for a negativity bias [J]. J Sleep Res, 2018, 27(2): 215-9.

[43] BONNET M H, ARAND D L. Insomnia, metabolic rate and sleep restoration [J]. J Intern Med, 2003, 254(1): 23-31.

[44] NOFZINGER E A, BUYSSE D J, GERMAIN A, et al. Functional neuroimaging evidence for hyperarousal in insomnia [J]. Am J Psychiat, 2004, 161(11): 2126-9.

[45] CARNEY C E, HARRIS A L, MOSS T G, et al. Distinguishing rumination from worry in clinical insomnia [J]. Behav Res Ther, 2010, 48(6): 540-6.

[46] KALMBACH D A, BUYSSE D J, CHENG P, et al. Nocturnal cognitive arousal is associated with objective sleep disturbance and indicators of physiologic hyperarousal in good sleepers and individuals with insomnia disorder * [J]. Sleep Med, 2020, 71: 151-60.

[47] 王继军, 王祖承. 老年人失眠的原因及治疗方法 [J]. 中国新药与临 床杂志, 2008, (02): 149-52.

[48] 刘连启, 王汝展, 刘贤臣, et al. 老年人睡眠质量及其相关因素研究 [J]. 中国老年学杂志, 2002, (06): 437-40.

[49] ROSENBERG R, CITROME L, DRAKE C L. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies [J]. Neuropsych Dis Treat, 2021, 17: 2549-66.

[50] CARNEY C E, SEGAL Z V, EDINGER J D, et al. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder [J]. J Clin Psychiatry, 2007, 68(2): 254-60.

[51] NIERENBERG A A, KEEFE B R, LESLIE V C, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine [J]. J Clin Psychiatry, 1999, 60(4): 221-5.

[52] BRAGG S, BENICH J J, CHRISTIAN N, et al. Updates in insomnia diagnosis and treatment [J]. Int J Psychiat Med, 2019, 54(4-5): 275-89.

[53] LIANG L, HUANG Y B, XU R, et al. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double- blind, randomized, placebo-controlled trials [J]. Sleep Med, 2019, 62: 6-13.

[54] HOHAGEN F, KAPPLER C, SCHRAMM E, et al. Sleep Onset Insomnia, Sleep Maintaining Insomnia and Insomnia with Early- Morning Awakening - Temporal Stability of Subtypes in a Longitudinal-Study on General-Practice Attenders [J]. Sleep, 1994, 17(6): 551-4.

[55] ROSENBERG R P. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies [J]. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2006, 18(1): 49-56.

[56] PILLAI V, ROTH T, DRAKE C L. The Nature of Stable Insomnia Phenotypes [J]. Sleep, 2015, 38(1): 127-U307.

[57] CHATTU V K, MANZAR M D, KUMARY S, et al. 9 The Global Problem of Insufficient Sleep and Its Serious Public Health Implications [J]. Healthcare-Basel, 2018, 7(1).

[58] VGONTZAS A N, FERNANDEZ-MENDOZA J, LIAO D P, et al. Insomnia with objective short sleep duration: The most biologically severe phenotype of the disorder [J]. Sleep Medicine Reviews, 2013, 17(4): 241-54.

[59] WU Y L, ZHAI L, ZHANG D F. Sleep duration and obesity among adults: a meta-analysis of prospective studies [J]. Sleep Med, 2014, 15(12): 1456-62.

[60] TAHERI S, LIN L, AUSTIN D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index [J]. Plos Med, 2004, 1(3): 210-7.

[61] PANDI-PERUMAL S R, MONTI J M, BURMAN D, et al. Clarifying the role of sleep in depression: A narrative review [J]. Psychiatry Res, 2020, 291: 113239.

[62] COLVONEN P J, STRAUS L D, STEPNOWSKY C, et al. Recent Advancements in Treating Sleep Disorders in Co-Occurring PTSD [J]. Curr Psychiatry Rep, 2018, 20(7): 48.

[63] VGONTZAS A N, LIAO D P, BIXLER E O, et al. Insomnia with Objective Short Sleep Duration is Associated with a High Risk for Hypertension [J]. Sleep, 2009, 32(4): 491-7.

[64] STAHL S M. Mechanism of Action of Trazodone: a Multifunctional Drug [J]. Cns Spectrums, 2009, 14(10): 536-46.

[65] SATEIA M J, BUYSSE D J, KRYSTAL A D, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline [J]. J Clin Sleep Med, 2017, 13(2): 307-49.

[66] CHENG P, KALMBACH D A, TALLENT G, et al. Depression prevention via digital cognitive behavioral therapy for insomnia: a randomized controlled trial [J]. Sleep, 2019, 42(10).

[67] ISHAK W W, BAGOT K, THOMAS S, et al. Quality of life in patients suffering from insomnia [J]. Innov Clin Neurosci, 2012, 9(10): 13-26.

[68] DALEY M, MORIN C M, LEBLANC M, et al. The Economic Burden of Insomnia: Direct and Indirect Costs for Individuals with Insomnia Syndrome, Insomnia Symptoms, and Good Sleepers [J]. Sleep, 2009, 32(1): 55-64.

[69] FOLEY D J, MONJAN A A, BROWN S L, et al. SLEEP COMPLAINTS AMONG ELDERLY PERSONS - AN EPIDEMIOLOGIC-STUDY OF 3 COMMUNITIES [J]. Sleep, 1995, 18(6): 425-32.

[70] TAYLOR D J, MALLORY L J, LICHSTEIN K L, et al. Comorbidity of chronic insomnia with medical problems [J]. Sleep, 2007, 30(2): 213-8.

[71] MORIN C M, BOOTZIN R R, BUYSSE D J, et al. Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998- 2004) [J]. Sleep, 2006, 29(11): 1398-414.

[72] 蔡少娜, 郑勇前, 陈文艺, et al. 针灸联合柴桂龙骨牡蛎汤治疗肝郁 型顽固性失眠的临床疗效 [J]. 内蒙古中医药, 2022, 41(01): 121-3.

[73] 张悦, 刘绍惠, 侯悦春. 针刺治疗药物依赖性失眠 [J]. 中国针灸, 2002, (03): 185.

[74] ALESSI C, MARTIN J L, FIORENTINO L, et al. Cognitive Behavioral Therapy for Insomnia in Older Veterans Using Nonclinician Sleep Coaches: Randomized Controlled Trial [J]. J Am Geriatr Soc, 2016, 64(9): 1830-8.

[75] PODDAR S K, SIFAT A E, HAQUE S, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule [J]. Biomolecules, 2019, 9(1).

[76] MILLS K F, YOSHIDA S, STEIN L R, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice [J]. Cell Metab, 2016, 24(6): 795-806.

[77] RAJMAN L, CHWALEK K, SINCLAIR D A. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence [J]. Cell Metab, 2018, 27(3): 529-47.

[78] OKABE K, YAKU K, TOBE K, et al. Implications of altered NAD metabolism in metabolic disorders [J]. J Biomed Sci, 2019, 26.

[79] HARDEN A, YOUNG W J, MARTIN C J. The alcoholic ferment of yeast-juice. Part II.—The coferment of yeast-juice [J]. Proceedings of the Royal Society of London Series B, Containing Papers of a Biological Character, 1906, 78(526): 369-75.

[80] VON EULER H, MYRBACK K. Co-zynase, XVII [J]. H-S Z Physiol Chem, 1930, 190: 93-100.

[81] CHAMBON P, MANDEL P, WEILL J D. Nicotinamide Mononucleotide Activation of a New DNA-Dependent Polyadenylic Acid Synthesizing Nuclear Enzyme [J]. Biochem Bioph Res Co, 1963, 11(1): 39-&.

[82] YOSHINO J, BAUR J A, IMAI S I. NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR [J]. Cell Metab, 2018, 27(3): 513-28.

[83] FRYE R A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity [J]. Biochem Bioph Res Co, 1999, 260(1): 273-9.

[84] ESCANDE C, NIN V, PRICE N L, et al. Flavonoid Apigenin Is an Inhibitor of the NAD(+)ase CD38 Implications for Cellular NAD(+) Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome [J]. Diabetes, 2013, 62(4): 1084-93.

[85] MICHAN S, SINCLAIR D. Sirtuins in mammals: insights into their biological function [J]. Biochem J, 2007, 404: 1-13.

[86] IMAI S, YOSHINO J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing [J]. Diabetes Obes Metab, 2013, 15 Suppl 3: 26-33.

[87] COVARRUBIAS A J, PERRONE R, GROZIO A, et al. NAD(+) metabolism and its roles in cellular processes during ageing [J]. Nat Rev Mol Cell Bio, 2021, 22(2): 119-41.

[88] CAMACHO-PEREIRA J, TARRAGO M G, CHINI C C S, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism [J]. Cell Metab, 2016, 23(6): 1127-39.

[89] YOSHINO J, MILLS K F, YOON M J, et al. Nicotinamide Mononucleotide, a Key NAD(+) Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice [J]. Cell Metab, 2011, 14(4): 528-36.

[90] GOMES A P, PRICE N L, LING A J Y, et al. Declining NAD(+) Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging [J]. Cell, 2013, 155(7): 1624-38.

[91] MOUCHIROUD L, HOUTKOOPER R H, MOULLAN N, et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling [J]. Cell, 2013, 154(2): 430- 41.

[92] CHINI C C S, TARRAGO M G, CHINI E N. NAD and the aging process: Role in life, death and everything in between [J]. Mol Cell Endocrinol, 2017, 455(C): 62-74.

[93] IMAI S, GUARENTE L. NAD+ and sirtuins in aging and disease [J]. Trends Cell Biol, 2014, 24(8): 464-71.

[94] GITIAUX C, BLIN-ROCHEMAURE N, HULLY M, et al. Progressive demyelinating neuropathy correlates with clinical severity in Cockayne syndrome [J]. Clin Neurophysiol, 2015, 126(7): 1435-9.

[95] SCHEIBYE-KNUDSEN M, MITCHELL S J, FANG E F, et al. A high- fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome [J]. Cell Metab, 2014, 20(5): 840-55.

[96] PREUGSCHAT F, CARTER L H, BOROS E E, et al. A pre-steady state and steady state kinetic analysis of the N-ribosyl hydrolase activity of hCD157 [J]. Arch Biochem Biophys, 2014, 564: 156-63.

[97] DE FLORA A, ZOCCHI E, GUIDA L, et al. Autocrine and paracrine calcium signaling by the CD38/NAD+/cyclic ADP-ribose system [J]. Ann N Y Acad Sci, 2004, 1028: 176-91.

[98] GROZIO A, SOCIALI G, STURLA L, et al. CD73 Protein as a Source of Extracellular Precursors for Sustained NAD(+) Biosynthesis in FK866-treated Tumor Cells [J]. J Biol Chem, 2013, 288(36): 25938-49.

[99] BOSLETT J, HEMANN C, ZHAO Y J, et al. Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H) [J]. J Pharmacol Exp Ther, 2017, 361(1): 99-108.

[100] YOUNG G S, CHOLERIS E, LUND F E, et al. Decreased cADPR and increased NAD(+) in the Cd38(-/-) mouse [J]. Biochem Bioph Res Co, 2006, 346(1): 188-92.

[101] ESSUMAN K, SUMMERS D W, SASAKI Y, et al. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD(+) Cleavage Activity that Promotes Pathological Axonal Degeneration [J]. Neuron, 2017, 93(6): 1334-+.

[102] GERDTS J, BRACE E J, SASAKI Y, et al. SARM1 activation triggers axon degeneration locally via NAD(+) destruction [J]. Science, 2015, 348(6233): 453-7.

[103] COSTFORD S R, BAJPEYI S, PASARICA M, et al. Skeletal muscle NAMPT is induced by exercise in humans [J]. Am J Physiol-Endoc M, 2010, 298(1): E117-E26.

[104] YAMAMOTO T, BYUN J, ZHAI P Y, et al. Nicotinamide Mononucleotide, an Intermediate of NAD(+) Synthesis, Protects the Heart from Ischemia and Reperfusion [J]. Plos One, 2014, 9(6).

[105] WANG X, HU X, YANG Y, et al. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death [J]. Brain Res, 2016, 1643: 1-9.

[106] CATON P W, KIESWICH J, YAQOOB M M, et al. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function [J]. Diabetologia, 2011, 54(12): 3083-92.

[107] KAWAMURA T, MORI N, SHIBATA K. β-Nicotinamide Mononucleotide, an Anti-Aging Candidate Compound, Is Retained in the Body for Longer than Nicotinamide in Rats [J]. Journal of Nutritional Science and Vitaminology, 2016, 62(4): 272-6.

[108] ZHANG H B, RYU D, WU Y B, et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice [J]. Science, 2016, 352(6292): 1436-43.

[109] ASHER G, GATFIELD D, STRATMANN M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation [J]. Cell, 2008, 134(2): 317-28.

[110] NAKAHATA Y, KALUZOVA M, GRIMALDI B, et al. The NAD+- Dependent Deacetylase SIRT1 Modulates CLOCK-Mediated Chromatin Remodeling and Circadian Control [J]. Cell, 2008, 134(2): 329-40.

[111] CHANG H C, GUARENTE L. SIRT1 Mediates Central Circadian Control in the SCN by a Mechanism that Decays with Aging [J]. Cell, 2013, 153(7): 1448-60.

[112] MAURY E, HONG H K, BASS J. Circadian disruption in the pathogenesis of metabolic syndrome [J]. Diabetes Metab, 2014, 40(5): 338-46.

[113] IMAI S I. "Clocks" in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging [J]. Bba-Proteins Proteom, 2010, 1804(8): 1584-90.

[114] NAKAHATA Y, SAHAR S, ASTARITA G, et al. Circadian Control of the NAD(+) Salvage Pathway by CLOCK-SIRT1 [J]. Science, 2009, 324(5927): 654-7.

[115] DAVIDSON A J, YAMAZAKI S, ARBLE D M, et al. Resetting of central and peripheral circadian oscillators in aged rats [J]. Neurobiol Aging, 2008, 29(3): 471-7.

[116] IMAI S, GUARENTE L. NAD(+) and sirtuins in aging and disease [J]. Trends in Cell Biology, 2014, 24(8): 464-71.

[117] PEEK C B, NATI A H A, RAMSEY K M, et al. Circadian Clock NAD(+) Cycle Drives Mitochondrial Oxidative Metabolism in Mice [J]. Science, 2013, 342(6158): 591-+.

[118] 王静, 侯婉婷, 秦雪梅, et al. 昼夜节律的相关研究进展 [J]. 中国中 药杂志, 2021, 46(13): 3240-8.

[119] YOSHINO M, YOSHINO J, KAYSER B D, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women [J]. Science, 2021, 372(6547): 1224-+.

[120] MASAKI I, MASAOMI M, YOSHIKO N-N, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle motility in healthy old men [J]. Research Square, 2022.

[121] LIAO B, ZHAO Y, WANG D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study [J]. J Int Soc Sports Nutr, 2021, 18(1): 54.

[122] KIM M, SEOL J, SATO T, et al. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study [J]. Nutrients, 2022, 14(4).

[123] 刚丽丽. 董氏奇穴结合耳尖放血治疗失眠的文献研究及临床研究 [D]; 北京中医药大学, 2021.

[124] 张鹏, 李雁鹏, 吴惠涓, et al. 中国成人失眠诊断与治疗指南(2017 版) [J]. 中华神经科杂志, 2018, 51(05): 324-35.

[125] 张鹏, 赵忠新. 《中国成人失眠诊断与治疗指南》解读 [J]. 中国现 代神经疾病杂志, 2013, 13(05): 363-7.

[126] 路桃影, 李艳, 夏萍, et al. 匹兹堡睡眠质量指数的信度及效度分析 [J]. 重庆医学, 2014, 43(03): 260-3.

[127] SCHUTTE-RODIN S, BROCH L, BUYSSE D, et al. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults [J]. J Clin Sleep Med, 2008, 4(5): 487-504.

[128] CHI J, CAO W, GU Y. Recent Progress in Sleep Quality Monitoring and Non-drug Sleep Improvement [J]. Front Hum Neurosci, 2020, 14.

[129] 刘建红. 阻塞性睡眠呼吸暂停低通气综合征诊治指南(基层版)解析; proceedings of the 2015 年全国睡眠呼吸学术年会, 中国宁夏银川, F, 2015 [C].

[130] BROWMAN C P, CARTWRIGHT R D. The first-night effect on sleep and dreams [J]. Biol Psychiatry, 1980, 15(5): 809-12.

[131] 韦哲, 石恒兵, 曹彤, et al. 国内外智能可穿戴设备的研究进展 [J]. 中国医学装备, 2020, 17(10): 18-21.

[132] 邢晅毓, 黄婉琪, 蓝宇涛, et al. 医学生体育活动量与睡眠质量相关 性研究 [J]. 卫生职业教育, 2021, 39(03): 119-21.

[133] 葛婷. 情感化设计在可穿戴设备中的应用——以小米手环 4 为例 [J]. 工业设计, 2020, (05): 113-4.

[134] KOLLA B P, MANSUKHANI S, MANSUKHANI M P. Consumer sleep tracking devices: a review of mechanisms, validity and utility [J]. Expert Rev Med Devices, 2016, 13(5): 497-506.

[135] 马黎娜, 聂煌, 季刚, et al. 可穿戴监测设备用于术后患者活动和睡 眠监测的准确性 [J]. 中华麻醉学杂志, 2020, 40(10): 1232-6.

[136] XIE J Q, WEN D, LIANG L Z, et al. Evaluating the Validity of Current Mainstream Wearable Devices in Fitness Tracking Under Various Physical Activities: Comparative Study [J]. JMIR Mhealth Uhealth, 2018, 6(4).

[137] CHEUNG J, LEARY E B, LU H Y, et al. PSG Validation of minute-to- minute scoring for sleep and wake periods in a consumer wearable device [J]. Plos One, 2020, 15(9).